Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ingo Flamme is active.

Publication


Featured researches published by Ingo Flamme.


Methods in Enzymology | 2007

Determination and Modulation of Prolyl‐4‐Hydroxylase Domain Oxygen Sensor Activity

Renato Wirthner; Kuppusamy Balamurugan; Daniel P. Stiehl; Sandra Barth; Patrick Spielmann; Felix Oehme; Ingo Flamme; Dörthe M. Katschinski; Roland H. Wenger; Gieri Camenisch

The prolyl-4-hydroxylase domain (PHD) oxygen sensor proteins hydroxylate hypoxia-inducible transcription factor (HIF)-alpha (alpha) subunits, leading to their subsequent ubiquitinylation and degradation. Since oxygen is a necessary cosubstrate, a reduction in oxygen availability (hypoxia) decreases PHD activity and, subsequently, HIF-alpha hydroxylation. Non-hydroxylated HIF-alpha cannot be bound by the ubiquitin ligase von Hippel-Lindau tumor suppressor protein (pVHL), and HIF-alpha proteins thus become stabilized. HIF-alpha then heterodimerizes with HIF-beta (beta) to form the functionally active HIF transcription factor complex, which targets approximately 200 genes involved in adaptation to hypoxia. The three HIF-alpha PHDs are of a different nature compared with the prototype collagen prolyl-4-hydroxylase, which hydroxylates a mass protein rather than a rare transcription factor. Thus, novel assays had to be developed to express and purify functionally active PHDs and to measure PHD activity in vitro. A need also exists for such assays to functionally distinguish the three different PHDs in terms of substrate specificity and drug function. We provide a detailed description of the expression and purification of the PHDs as well as of an HIF-alpha-dependent and a HIF-alpha-independent PHD assay.


Journal of Pineal Research | 2008

The impact of N-nitrosomelatonin as nitric oxide donor in cell culture experiments

Utta Berchner-Pfannschmidt; Suzan Tug; Buena Trinidad; Maria Becker; Felix Oehme; Ingo Flamme; Joachim Fandrey; Michael Kirsch

Abstract:  N‐Nitrosomelatonin (NOMela) is well‐known for its capabilities of transnitrosating nucleophiles such as thiols and ascorbate, thereby generating nitric oxide (NO)‐releasing compounds. It is unknown, however, whether NOMela can be successfully applied as a precursor of NO in a complex biological environment like a cell culture system. NO donors may be useful to induce the transcription factor hypoxia inducible factor 1 (HIF‐1), which coordinates the protection of cells and tissues from the lack of oxygen (hypoxia). In this study, the effects of NOMela in an in vitro cell‐free assay [NO‐release, inhibition of prolylhydroxylase1 (PHD1)] and in living cells (upregulation of HIF‐1, reduction of HIF‐1 hydroxylation, upregulation of the HIF‐1‐target gene PHD2) were compared with those of the frequently applied NO donor S‐nitrosoglutathione (GSNO) under normoxic and hypoxic conditions. In contrast to GSNO, NOMela released NO in a predictable manner and this release in vitro was found to be independent of the composition of the buffer system. The NOMela‐mediated effects in oxygenated cells were in all cases comparable to the hypoxic response, whereas unphysiological strong effects were observed with GSNO. Probably, because of the antioxidative power of the NOMela‐dependent formation of melatonin, cells were completely protected against the attack of reactive nitrogen oxygen species, which are generated by autoxidation of NO. In conclusion, NOMela had to be an excellent NO precursor for cells in culture and potentially tissues.


Analytical Biochemistry | 2004

A nonradioactive 96-well plate assay for the detection of hypoxia-inducible factor prolyl hydroxylase activity.

Felix Oehme; Willi Jonghaus; Laila Narouz-Ott; Joachim Huetter; Ingo Flamme


Archive | 2007

New substituted heteroaryl compounds are hypoxia-inducible factor prolyl-4-hydroxylase inhibitors useful to treat and/or prevent e.g. circulatory heart diseases, heart failure, anemia, chronic kidney diseases and renal failure

Hartmut Dr. Beck; Ingo Flamme; Mario Jeske; Felix Oehme; Friederike Stoll; Kai Thede


Archive | 2007

New substituted dihydropyrazole-3-thione compounds are hypoxia inducible factor-prolyl-4-hydroxylase inhibitor, useful for preparing medicament to treat and/or prevent e.g. cardiovascular diseases, wound healing and anemia

Ingo Flamme; Mario Jeske; Felix Oehme; Friederike Stoll


Archive | 2007

New substituted 2,3-dihydro-(1,2,3)triazol-4-one compounds are hypoxia inducible factor-prolyl-4-hydroxylase inhibitor, useful for preparing medicament to treat and/or prevent e.g. cardiovascular diseases, inflammatory disease and anemia

Metin Akbaba; Ingo Flamme; Mario Jeske; Felix Oehme; Friederike Stoll


Archive | 2007

Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung

Heinrich Meier; Eckhard Dr. Bender; Ulf Brüggemeier; Ingo Flamme; Dagmar Karthaus; Peter Kolkhof; Daniel Meibom; Dirk Schneider; Verena Voehringer; Chantal Fürstner; Joerg Keldenich; Dieter Lang; Elisabeth Pook; Carsten Schmeck


Archive | 2003

Regulation of novel human asparagine-hydroxylases

Ingo Flamme; Felix Oehme; Peter Ellinghaus


The Open Conference Proceedings Journal | 2011

Graduate Program in Pharmacology and Experimental Therapeutics – A Joint Endeavor of the University of Cologne and Bayer Schering

Stefan Herzig; Marion Rozowski; Ingo Flamme


Archive | 2006

New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure

Jens-Kerim Ergüden; Ingo Flamme; Peter Kolkhof; Felix Oehme; Joachim Schuhmacher; Friederike Stoll; Kai Thede; Hanno Wild

Collaboration


Dive into the Ingo Flamme's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge